Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06202625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Study acronym: Haplo-HSCT
StatusRecruiting
PhasePhase 2/3
Started2024-05-13
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 1, 2024 (before its estimated October 30, 2024 completion). Its status may not reflect the trial's current state.

Amendment history

2024-09-29
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-01-15→confirmed 2024-05-13
Study sites10→14
2024-01-01
minor
Original filing
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
Trial Details
NCT Number NCT06202625
Lead Sponsor Peking University People's Hospital
Collaborators: Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University
Conditions Thrombocytopenia, Stem Cell Transplant Complications
Enrollment 142 participants
Start Date 2024-05-13
Primary Completion 2024-10-30 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-01